论文部分内容阅读
利用多巴胺(DOPA)在有氧碱性溶液下形成聚多巴胺(PDA)的性质,以阿仑膦酸钠(ALD)为模型药物,作者制备了空白聚多巴胺纳米粒(PDA-NP)和载阿仑膦酸钠的聚多巴胺纳米粒(PDA-ALD-NP),并对这两种纳米粒的粒径及Zeta电位、形貌、稳定性、载药量、体外释放、摩擦学性能以及细胞毒性等进行了初步考察.结果表明,二者平均粒径均小于102nm,分布较窄,Zeta电位均在-25mV左右.用扫描电子显微镜(SEM)观察两种纳米粒形貌,显示PDA-NP和PDA-ALD-NP光滑圆整.紫外可见分光光度法(UV-Vis)测得PDA-ALD-NP载药量为5.3%±1.2%,体外释放结果表明PDA-ALD-NP明显减缓了ALD的释放.体外稳定性实验结果显示,PDA-ALD-NP在水溶液和胎牛血清(FBS)中能够保持一定程度的稳定.摩擦学考察结果显示PDA-ALD-NP具有较好的摩擦学性能.此外,采用MTT法考察了DOPA和两种纳米粒的生物相容性.
The use of dopamine (DOPA) to form polydopamine (PDA) under aerobic alkaline solution, using alendronate sodium (ALD) as a model drug, the authors prepared blank dopamine nanoparticles (PDA-NP) (PDA-ALD-NP), and their particle size and Zeta potential, morphology, stability, drug loading, in vitro release, tribological properties and cytotoxicity Etc. The results showed that the average particle sizes of the two nanoparticles were less than 102 nm and the distribution was narrow.The Zeta potential was about -25 mV.The morphologies of the two nanoparticles were observed by scanning electron microscopy (SEM) PDA-ALD-NP was smooth and rounded.The PDA-ALD-NP drug loading was 5.3% ± 1.2% measured by UV-Vis.The in vitro release results showed that PDA-ALD-NP significantly slowed the progression of ALD Release in vitro.The results of in vitro stability show that PDA-ALD-NP can maintain a certain degree of stability in aqueous solution and fetal bovine serum (FBS) .Friction results show that PDA-ALD-NP has good tribological properties. , The biocompatibility of DOPA and two kinds of nanoparticles were investigated by MTT method.